Skip to main content
. 2016 Jul 19;7(31):49027–49041. doi: 10.18632/oncotarget.10717

Figure 3. urantide inhibits secretions of IFN-β, IL-6 and IFN-γ in LPS-stimulated KCs.

Figure 3

KCs were treated with UII or urantide 0.5 h before LPS stimulation. Secretion levels of IFN-β, IL-6 and IFN-γ in KCs. Culture supernatant were assayed for IFN-β, IL-6 and IFN-γ via ELISA. Data represent means ± SD (n = 6). *P<0.05 and **P<0.01 versus control cells [UII(-)urantide(-)LPS(-)]; #P<0.05 and ##P<0.01 versus LPS-stimulated cells [UII(-)urantide(-)LPS(+)].